Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;48(5):503-10.
doi: 10.1111/cpr.12202. Epub 2015 Jul 22.

MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer

Affiliations
Review

MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer

Xin Yu et al. Cell Prolif. 2015 Oct.

Abstract

Colorectal cancer (CRC) is the fourth leading cause of cancer-related death globally. Chemotherapy regimens consisting of 5-fluorouracil (5-FU) in combination with either oxaliplatin or irinotecan are the first-line options for treatment of metastatic CRC. However, primary or acquired resistance to these chemotherapeutics is a major clinical challenge. MicroRNAs (miRNAs) are a group of small non-coding RNAs that regulate gene expression post-transcriptionally. miRNAs play important roles in many cancer-related processes, including cell proliferation, apoptosis and invasion, and their dysregulation is implicated in colorectal tumourigenesis. Pertinent to chemotherapy, increasing evidence has revealed that miRNAs can be directly linked to chemosensitivity in CRC. In this review, we summarize current evidence concerning the role of miRNAs in prediction and modulation of cellular responses to 5-FU, oxaliplatin and irinotecan in CRC. We also discuss the possible targets and intracellular pathways involved in these processes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Modulation of 5‐FU chemosensitivity by chemosensitizing and chemoresistant miRNAs in CRC.

Similar articles

Cited by

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J. Clin. 61, 69–90. - PubMed
    1. Sung JJ, Lau JY, Goh KL, Leung WK, Asia Pacific Working Group on Colorectal C (2005) Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 6, 871–876. - PubMed
    1. Edwards MS, Chadda SD, Zhao Z, Barber BL, Sykes DP (2012) A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis. 14, e31–e47. - PMC - PubMed
    1. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M et al (2009) Safety and efficacy of first‐line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 20, 1842–1847. - PubMed
    1. Temraz S, Mukherji D, Alameddine R, Shamseddine A (2014) Methods of overcoming treatment resistance in colorectal cancer. Crit. Rev. Oncol. Hematol. 89, 217–230. - PubMed

Publication types

MeSH terms